FiercePharma1d
EU drug reviewers back Novo Nordisk’s FDA-rejected hemophilia drug, snub PTC’s Translarna again
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
On Friday, Novo Nordisk A/S (NYSE:NVO) said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
The Pharma Letter6d
FDA approves new treatment for hemophilia A or B
The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
biopharma-reporter4d
FDA approves Pfizer's antibody treatment for hemophilia
The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
FiercePharma7d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Monthly Prescribing Reference4d
Hympavzi Approved for Treatment of Hemophilia A or B
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
Healthline10d
Your Guide to Treatment Options for Hemophilia B
Hemophilia B is a genetic disorder that affects how well your blood clots. Treatment includes supplementing the protein factor IX, but new therapies may offer alternative ways to manage factor IX ...